Autolus Therapeutics (NASDAQ:AUTL) Issues Earnings Results, Beats Expectations By $0.12 EPS

Autolus Therapeutics (NASDAQ:AUTL) released its quarterly earnings data on Thursday. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.12, Zacks reports.

Autolus Therapeutics Stock Performance

Shares of Autolus Therapeutics stock opened at $1.92 on Thursday. The company has a market capitalization of $509.57 million, a PE ratio of -1.61 and a beta of 2.07. The company has a 50-day simple moving average of $2.05 and a two-hundred day simple moving average of $2.94. Autolus Therapeutics has a one year low of $1.68 and a one year high of $6.63.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research note on Monday, January 13th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Autolus Therapeutics presently has an average rating of “Buy” and an average target price of $10.40.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.